User Tools


Editorial Board

Betty Diamond, MD
The Feinstein Institute for Medical Research
Manhasset, NY, USA


Frederick W Alt, PhD
Howard Hughes Medical Institute
Children's Hospital
Boston, MA, USA

Marco E Bianchi, PhD
San Raffaele Scientific Institute
Milan, Italy

Timothy Billiar, MD
University of Pittsburgh, School of Health Science
Pittsburgh, PA, USA

Michael Bukrinsky, MD, PhD
George Washington University
Washington, DC, USA 

Anthony Cerami, PhD
Editor Emeritus
Araim Pharmaceuticals
Tarrytown, NY, USA
Nicholas Chiorazzi, MD
The Feinstein Institute for Medical Research
Manhasset, NY, USA 
Robert J Desnick, MD, PhD
Mount Sinai School of Medicine
New York, NY, USA 
Charles A Dinarello, MD
University of Colorado Health Sciences
Denver, CO, USA 
Hannelore Ehrenreich, MD
Max-Planck Institute for 
Experimental Medicine
Goettingen, Germany

Laurie Glimcher, MD
Weill Cornell Medicine
New York, NY, USA
Paul Greengard, PhD
Rockefeller University
New York, NY, USA 
Peter K Gregersen, MD
The Feinstein Institute for Medical Research
Manhasset, NY, USA 
Lars Klareskog, MD, PhD
Karolinska Institute
Stockholm, Sweden 

Mike McCune, MD, PhD
University of California, San Francisco
San Francisco, CA, USA
Carl F Nathan, MD
Weill Cornell Medicine
New York, NY, USA 
Bert W O'Malley, MD
Baylor College of Medicine
Houston, TX, USA 
Athanasios G Papavassiliou,
University of Athens
Athens, Greece 
Arthur B Pardee, PhD
Dana Farber Cancer Institute
Boston, MA, USA 
Marc H Symons, PhD
The Feinstein Institute for Medical Research
Manhasset, NY, USA 
Csaba Szabo MD, PhD
University of Texas Medical Branch
Galveston, TX, USA

Kevin J Tracey, MD
Editor Emeritus
The Feinstein Institute for Medical Research
Manhasset, NY, USA

H Shaw Warren MD
Infectious Disease Unit
Massachusetts General Hospital
Charlestown, MA, USA

Editorial Process

Following is an outline describing the editorial process for Molecular Medicine.

The mission of Molecular Medicine is to publish recent original findings that elucidate the pathogenesis of disease at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing original material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication if neither the article nor any part of its essential substance, tables, or figures has been or will be published or submitted elsewhere before appearing in Molecular Medicine. Manuscripts published in Molecular Medicine should contain human or animal in vivo or ex vivo data and describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.

Publication Decisions
Molecular Medicine's Editors, not its reviewers, judge which submissions will appeal to our broad audience. Reviewers contribute constructive reports and comments, and suggest preliminary decisions. Publication is informed by prominence, significance, and timeliness of the findings, as well as general appeal of the work to a broad audience.

Pre-submission Enquiries 
Please see: For Authors

Cover Letter
Please see: For Authors

Once submitted, a manuscript will be reviewed by the Editors who consider whether to send the work for peer-review. The manuscript deemed suitable for the journal will be assigned to an Editor who has agreed to undertake its rapid review, soliciting the opinions of independent reviewers. While authors are required to submit three potential reviewers, Editors are free to decide whom to invite for a review. Editors normally honor requests that a manuscript not be sent to competing groups for review. Most manuscripts receive two or three reviews, however, some receive more, and occasionally some receive just one. Reviewers are chosen based on their independence from the authors, ability to evaluate technical aspects of the paper fairly, availability to return a review within the required timeframe, and quality of previous reviews (if applicable). Reviewers report on: whether the manuscript contributes to our understanding of disease pathogenesis; whether the work includes a molecular tool for disease diagnosis, treatment or prevention; what audience the work will appeal to and why; and any technical issues that may need to be addressed. Reviewers then make a recommendation on whether to accept, defer a decision, or reject the work. Instructions for reviewers.

Once a manuscript has undergone a round of review, authors will receive one of the following decisions:

  • Accept – the manuscript is accepted for publication, no further changes required;
  • Accept, Minor – the manuscript is accepted for publication in principle, once the authors have made revisions requested by reviewers;
  • Decision Deferred – a final decision on publication is deferred, pending the authors' response to the reviewers' comments;
  • Reject – the paper is rejected with no offer to reconsider a resubmitted version.

Open Access
Molecular Medicine is an open access publication. All content is published free online, ahead of print, on the website These documents are marked "uncorrected proof" and will be replaced at a later date with final author-approved PDFs. Papers are also posted rapidly to PubMed with an e-publication ahead of print citation. Work will automatically be submitted to PubMed Central according to the NIH Public Access Policy. Following author approval, final PDFs will be submitted to the National Library of Medicine. Molecular Medicine does not embargo content.

This is an open access journal which means all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access. Molecular Medicine's open access policy.

After acceptance, the production staff copyedits the manuscript. This ensures the work conforms to Molecular Medicine's house style and that figures and tables are of publication quality, clarity and size. Authors will then receive a proof, which may include queries to be addressed. The corresponding author is responsible for completing this work with the production staff. The corresponding author is responsible for the accuracy of content, spelling of names and affiliations of all co-authors.

Final author-approved PDF papers will be posted to PubMed and PubMed Central on a rolling basis. Users wishing to purchase a single issue, a special issue, a back issue, offprints, reprints, or individual copies of a manuscript can visit our Print-on-Demand page. For questions, please contact

Molecular Medicine's Editors are unable to assign high priority to consideration of appeals. The appeals process is time intensive and Molecular Medicine's Editors may be delayed in responding while reviewing individual cases. Manuscripts must not be submitted for publication elsewhere during this time. Appeals must be made in writing ( and should be restricted to the scientific case for publication.

Contact Information
The Feinstein Institute for Medical Research
Editorial Offices of Molecular Medicine
350 Community Drive
Manhasset, NY 11030
Telephone: (516) 562-2114
Fax: (516) 562-1022